WILLIAM DELANCEY: Open Payments
NPI 1285335760 · RACELAND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,490 in 145 payments from 14 companies in 2025. Trend: 2023 $2,167 · 2024 $2,034 · 2025 $2,490
Food & beverage: $2,379Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $365 |
| Alkermes, Inc. | 19 | $312 |
| Otsuka America Pharmaceutical, Inc. | 15 | $301 |
| Teva Pharmaceuticals USA, Inc. | 12 | $281 |
| E.R. Squibb & Sons, L.L.C. | 14 | $197 |
| Vanda Pharmaceuticals Inc. | 11 | $189 |
| Lundbeck LLC | 15 | $179 |
| ABBVIE INC. | 11 | $154 |
| Neurocrine BioSciences, Inc. | 9 | $144 |
| Janssen Pharmaceuticals, Inc | 6 | $141 |
Products named: CAPLYTA, REXULTI, ARISTADA, COBENFY, FANAPT, VRAYLAR, INGREZZA, Auvelity.
Industry payments across LA — which companies pay providers there.
